Matthew Brunner, MD, discusses how to best approach the navigation of advanced imaging modalities in relapsed/refractory multiple myeloma.
Recent Content
- Dr Deol on the Current Limitations of CAR T-cell Therapy in R/R Myeloma
- CT-defined body composition as a prognostic factor in multiple myeloma
- MRD Testing Made a Myeloma Survivor Feel ‘OK to Be Safe’
- CAR T-Cell Therapy for Multiple Myeloma: Eliminating Disparities Through Accountability
- Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy
- Different Translocations of Multiple Myeloma on Fluorescent <em>In Situ</em> Hybridization (FISH) with Clinical Correlation
- Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy
- Isatuximab in multiple myeloma
- Dr. Godara on Approved CAR T-cell Therapies in Multiple Myeloma
- Ixazomib, Oral Metronomic Cyclophosphamide, and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study